We evaluated the effects of natural purine and pyrimidine nucleosides on protection from or reversal of 3'-azido-3'-deoxythymidine (AZT) cytotoxicity in human bone marrow progenitor cells by using clonogenic assays. The selectivity of the "protection" or "rescue" agents was examined in evaluating the antiretroviral activity of AZT in combination with these modulating agents and of AZT alone. Following exposure of human granulocyte-macrophage progenitor cells for 2 h to 5 ,uM AZT (70% inhibitory concentration), increasing concentrations of potential rescue agents were added. Cells were cultured, and colony formation was assessed after 14 days. At concentrations of up to 50 ,uM no natural 2'-deoxynucleosides, including thymidine, were able to reverse the toxic effects of AZT. Dose-dependent reversal was observed with uridine and cytidine, and essentially complete reversal was achieved with 50 ,uM uridine. In the protection studies, 100 ,uM thymidine almost completely antagonized the inhibition of granulocyte-macrophage colony formation produced by 1 ,zM AZT (50% inhibitory concentration), and 50 ,uM uridine effected 60% protection against a toxic concentration of AZT (5 ,uM) (70% inhibitory concentration). The antiretroviral activity of AZT in human peripheral blood mononuclear cells, assessed by reverse transcriptase assays, was substantially decreased in the presence of thymidine, whereas no impairment of suppression of viral replication was observed in the presence of uridine in combination with AZT at a molar ratio (uridine/AZT) as high as 10,000. This demonstration of the capacity of uridine to selectively rescue human bone marrow progenitor cells from the cytotoxicity of AZT suggests that use of uridine rescue regimen with AZT may have potential therapeutic benefit in the treatment of acquired immunodeficiency syndrome.
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3'-Azido-3'-deoxythymidine (AZT), a pyrimidine nucleoside synthesized two decades ago by Horwitz et al. (7) , has recently been shown to transiently improve certain immunological functions in some patients with acquired immunodeficiency syndrome (AIDS) (3), resulting in a decrease in the incidence of opportunistic infections and prolonging survival. The antiretroviral effects of AZT are probably based upon its conversion through cellular kinases to AZT triphosphate, which binds to reverse transcriptase and thereby inhibits viral DNA synthesis by chain termination (4) . Although AZT selectively inhibits the replication of human immunodeficiency virus type 1 (HIV) (10), its applications in preliminary clinical trials (11, 15) were limited by expressions of bone marrow toxicity. Consistent with these expressions we recently reported (12) that continuous exposure to AZT for 14 days effected a dose-dependent inhibition of human granulocyte-macrophage CFU (CFU-GM) and erythroid burst-forming unit colonies, the 50% inhibitory concentrations being 0.9 ± 0.1 and 2.4 ± 0.4 ,uM for the respective colonies. Several pharmacologic approaches are potentially available to improve the chemotherapeutic selectivity of AZT. Such an improvement can be theoretically obtained with synergistic combination chemotherapy, as recently demonstrated with recombinant human granulocyte-macrophage colony-stimulating factor (5) and alpha A interferon (6) , potentially allowing a reduction in AZT concentrations. Selective "protection" or "rescue" combinations may also achieve this goal. In this approach, the * Corresponding author. modulating agents are used at a time and a dosage that counteract (protection) or reverse (rescue) the toxic effects in the host cell without interfering with the chemotherapeutic activity. This concept has been previously used in cancer chemotherapy with methotrexate and its "antidote," leucovorin (2), and more recently for treating protozoan infections with trimetrexate and leucovorin in AIDS patients (1) .
The present report relates the results of an evaluation of the capacities of various natural nucleosides to protect or to reverse AZT toxicity in human host cells. (8) and had a purity of >99%, as assessed by high-pressure liquid chromatography. The structure of the compound was confirmed by proton nuclear magnetic resonance, 13C nuclear magnetic resonance, and infrared spectroscopy. Other chemicals were of the highest quality commercially possible.
Virus strains. HIV strain LAV was obtained from the Centers for Disease Control, Atlanta, Ga., and propagated as recently described (13) . Preparation of cells. Human bone marrow cells were collected by aspiration from the posterior iliac crest of normal healthy volunteers and treated with heparin, and the mononuclear population was separated by Ficoll-Hypaque gradient centrifugation. Cells were washed twice in Hanks balanced salt solution and counted with a hemacytometer, and their viability was >98%, as assessed by trypan blue exclusion. Peripheral blood mononuclear (PBM) cells were obtained from the whole blood of healthy HIV-and hepatitis B virus-seronegative volunteers and collected by single-step Ficoll-Hypaque discontinuous gradient centrifugation.
Assay of CFU-GM for drug cytotoxicity and rescue or protection studies. The culture assay of CFU-GM was performed by a bilayer soft-agar method as recently described (12) . McCoy 5A nutrient medium supplemented with 15% dialyzed fetal bovine serum (heat inactivated at 56°C for 30 min) (GIBCO Laboratories, Grand Island, N.Y.) was used in all experiments. This medium completely lacked thymidine and uridine.
In the rescue studies, mononuclear cells (105/ml) were exposed for 2 h at 37°C in 5 ml of McCoy 5A nutrient medium to 5 ,uM AZT, corresponding to a 70% inhibitory concentration. At the end of the 2-h incubation period, cells were washed twice with fresh cold incubation medium to wash out the AZT. Cells were subsequently cloned in 0.3% agar in the presence of increasing concentrations of the modulating compound or in medium alone (control). After 14 days of incubation at 37°C in a humidified atmosphere of 5% CO2 in air, colonies (250 cells) were counted by using an inverted microscope.
In the protection studies, AZT (1 or 5 ,M) and either medium (control) or various concentrations of thymidine or uridine were added simultaneously. Cells were exposed continuously under these conditions for 14 days, and colonies (.50 cells) were then scored. The toxicity of each purine and pyrimidine analog investigated in these studies (see Table 1 ) was assessed by continuous exposure for 14 days by the same technique.
Anti-HIV assay based on reverse transcriptase activity. After phytohemagglutinin stimulation for 3 days, PBM cells (5 x 105/ml) were infected with HIV strain LAV at a concentration of about 100 50% tissue culture infective doses per ml and cultured in the presence of various concentrations of AZT alone or in combination with either uridine or thymidine. The virus was allowed to adsorb for 45 min, and then drugs (AZT and uridine or thymidine) were added. A virus control (no drug) and a cell control (no virus or drug) were also included. On day 5 after infection, clarified supernatant fluids were centrifuged in a Beckman 70.1 Ti rotor at 40,000 rpm for 30 min. The concentrated, disrupted virus was subjected to reverse transcriptase assays as recently described by Spira et al. (13) . Antiretroviral efficacy was determined by calculating the percent reduction in reverse transcriptase activity observed in drug-treated, virus-infected cultures as compared with enzyme activity in virusinfected control cultures.
RESULTS
Effect of a short exposure (2 h) of normal human bone marrow progenitor cells to AZT on colony growth. Initial experiments were designed to establish the concentration dependence of human bone marrow progenitor cell toxicity produced by AZT after 2 h of drug exposure. Normal human bone marrow cells were incubated at 37°C for 2 h with various concentrations of AZT, and cells were washed twice prior to plating. Cell viability was determined by soft-agar cloning and measurement of colony formation after drug treatment as described in Materials and Methods. After 2 h of drug exposure, the toxic effects of AZT ( Fig. 1) were quite similar to those recently reported for these cells after continuous exposure (14 days) to AZT (12) , suggesting that the toxicity of AZT in human bone marrow progenitor cells in vitro is probably mediated through early effects. Ability of purine or pyrimidine derivatives to reverse the toxicity of AZT adding purine or pyrimidine nucleoside analogs to human hematopoietic progenitor cells following 2 h of exposure to 5 ,uM AZT (70% inhibitory dose) are shown in Table 1 . No natural purine or pyrimidine 2'-deoxynucleosides (2'-deoxyuridine, 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, and thymidine) up to a concentration of 50 puM reversed the toxic effects of AZT, nor was reversal achieved with 2'-deoxynucleoside concentrations of up to 200 p,M (data not shown). In contrast, nontoxic concentrations of uridine or cytidine effected a significant and dose-dependent reversal of AZT toxicity. Essentially complete reversal was achieved with 50 ,uM uridine, and no significant difference was detected in the presence of higher concentrations of uridine (100 ,uM). At concentrations of 50 ,uM the rescue effect of cytidine was less than that of uridine. The reversal of AZT toxicity by cytidine probably depends on the conversion of cytidine to uridine by cytidine deaminase, a requirement that could explain the difference in the rescue potencies of the two pyrimidine derivatives.
Protection from AZT toxicity by uridine in human bone marrow cells. Simultaneous exposure to 5 ,uM AZT (70% inhibitory dose) and various concentrations of uridine was also investigated in our studies to assess whether uridine could protect human bone marrow progenitor cells from AZT toxicity when both drugs were present throughout the experiment. Figure 2 illustrates the effects of 5 ,uM AZT on hematopoietic colony growth of normal human bone marrow progenitor cells in the presence of 5 to 50 ,uM uridine. Dose-dependent protection was observed, with 50 p,M uridine effecting approximately 60% protection in the presence of a toxic concentration of AZT (5 p.M).
Protection from AZT toxicity by thymidine in human bone marrow cells. Since thymidine counteracts the antiretroviral activity of AZT in ATH8 cells (10) and both AZT and thymidine appear to share the same activating enzymes (i.e., thymidine and thymidylate kinases) (4), protection from AZT toxicity by thymidine was investigated in human bone marrow progenitor cells. Human granulocyte-macrophage precursor cells, grown in soft agar, were exposed continuously for 14 manner, almost complete protection being effected by 100 ,uM thymidine (Fig. 3) . Effect of thymidine and uridine on the antiretroviral activity of AZT in HIV-infected human PBM cells. The effects of thymidine and uridine on the capacity of AZT to inhibit HIV replication in human PBM cells was evaluated (Table 2) . Essentially full protection against HIV production was achieved with AZT alone at a concentration of approximately 0.01 p.M, in agreement with recently published data (9) . The presence of thymidine led to a substantial loss of the antiretroviral activity of AZT, as reported previously (10) . A concentration of 10 ,uM thymidine reduced the inhibition of HIV by 0.01 ,uM AZT by approximately 50%, and the anti-HIV activity of 0.01 ,uM AZT was essentially abolished by 100 ,uM thymidine. In contrast, concentrations of uridine of up to 100 ,uM and in combination with AZT at a molar a The mean of triplicate counts (± standard deviation) for the virus control was 234,780 ± 26,600 dpm/ml (equivalent to an approximate incorporation of 3.6 pmol of dTMP into the acid-unsoluble product). Counts for the blank and negative control (no virus or drug) were 355 and 1,535 dpm, respectively. A positive control for the reverse transcriptase assay was also included (count, 313,000 dpm).
ratio (uridine/AZT) as high as 10,000 had no effect on the antiretroviral activity of AZT. Cell viability and growth, as assessed by trypan blue exclusion and with a Coulter Counter, were similar among the cultures, and no toxicity was observed in the presence of 100 ,uM uridine (Table 3) . These data suggest that, unlike thymidine, uridine does not interfere with the uptake and/or metabolic activation of AZT in HIV-infected human PBM cells or any other mechanism(s) by which AZT inhibits HIV replication.
DISCUSSION
In a previous report from this laboratory, we demonstrated that AZT directly suppressed human hematopoietic colony growth in a dose-dependent manner by direct interaction with CFU-GM and erythroid burst-forming unit progenitor cells (12) . These findings were consistent with the observation that anemia and neutropenia were the major adverse effects of AZT administration to AIDS patients (11, 15) . In an effort to obviate this untoward effect of AZT, we have sought to determine in the present study whether natural nucleosides can protect against or reverse the toxicity of AZT in human bone marrow progenitor cells without affecting the antiretroviral activity of AZT. As reported here, thymidine can counteract or protect against the toxicity of AZT in normal human bone marrow cells, but it also antagonizes the antiretroviral activity of AZT (Table 2) . These data probably reflect a decrease in the formation of AZT triphosphate, since both AZT and thymidine utilize the same activating enzymes (i.e., thymidine and thymidylate kinases) to exert their pharmacologic action. It is particularly important that thymidine, even at concentrations of up to 100 ,uM, was not able to reverse the toxic effects of 5 ,uM AZT (70% inhibitory concentration) for human granulocytemacrophage precursor cells. This result suggests that the administration of thymidine sequentially with AZT in vivo probably will not prevent its toxic effects, as previously speculated (11) .
Our experiments also showed that the hematopoietic toxicity of AZT was consistently reversed by uridine and to a lesser extent by cytidine. The inhibition of CFU-GM colony formation at an AZT concentration of 5 ,uM was essentially reversed when 50 ,uM uridine was added to the cultures. The percentage of rescue of CFU-GM colony formation was proportional to the concentration of uridine, suggesting that the reversal was a competitive process. The same concentration of cytidine only partially reversed the toxic effects of AZT on colony formation. In these studies, cytidine probably acted through its conversion to uridine by cytidine deaminase, explaining the quantitative difference in the rescue between the two pyrimidine derivatives. Uridine was shown also to protect normal human bone marrow progenitor cells from AZT toxicity, and 60% protection was achieved when cells were exposed to both 5 ,uM AZT 
